Skip to content

Hypertonic Saline Solution in Heart Failure

Hypertonic Saline Solution in Decompensated Heart Failure

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00555685
Enrollment
34
Registered
2007-11-09
Start date
2008-02-29
Completion date
2010-12-31
Last updated
2014-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Renal Failure, Hyponatremia

Keywords

Heart Failure, Renal failure, Hyponatremia

Brief summary

Patients with decompensated heart failure have high rates of mortality and morbidity despite recent improvements in diagnosis and treatment. Some aspects of their presentation such as renal failure, hyponatremia and congestive phenomena have received special attention, as they are associated with worse prognosis. The infusion of hypertonic saline solution has been tested in different conditions of cardiovascular collapse. Current evidence indicates that the infusion of hypertonic solution in heart failure patients can provide clinical and haemodynamic improvement. The investigators are testing the hypothesis that the infusion of hypertonic solution in association with diuretics may prevent the occurrence of renal dysfunction in patients with decompensated heart failure.

Interventions

DRUGNaCl 7,5% (Hypertonic Saline Solution)

Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days

Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days

Sponsors

Fundação de Amparo à Pesquisa do Estado de São Paulo
CollaboratorOTHER_GOV
University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age over 18 years old * Heart failure according to Framingham criteria * Episode of acute decompensation,with need of in-hospital treatment * Presence of congestive phenomena

Exclusion criteria

* Patient denial * Left-ventricle ejection fraction over 0,4, as measure by transthoracic echocardiography * Rheumatic disease * Restrictive cardiomyopathy * Alcohol abuse * Chronic obstructive pulmonary disease * Cancer * Pulmonary embolism during the last 6 months * Surgical procedures or acute illness during the last 30 days * Chronic or acute infection * Any other circumstance that may hamper patient prognosis for the next 6 months * Serum creatine over 3.0mg/dL * Serum potassium over 5.5 mEqs/L * Any specific condition associated to the acute episode of decompensation, such as new onset cardiac arrhythmias, heart ischemia, infection, etc.

Design outcomes

Primary

MeasureTime frame
Occurrence of renal disfunctionDuring hospital admission

Secondary

MeasureTime frame
Improvement of hyponatremiaDuring hospital admission
Improvement of congestive phenomenaDuring hospital admission

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026